CN1682780A - 一种治疗尿毒症及肾阳虚、肾衰竭的药物及其制备方法 - Google Patents
一种治疗尿毒症及肾阳虚、肾衰竭的药物及其制备方法 Download PDFInfo
- Publication number
- CN1682780A CN1682780A CN 200410021299 CN200410021299A CN1682780A CN 1682780 A CN1682780 A CN 1682780A CN 200410021299 CN200410021299 CN 200410021299 CN 200410021299 A CN200410021299 A CN 200410021299A CN 1682780 A CN1682780 A CN 1682780A
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- kidney
- rhizoma
- weight ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 93
- 229940079593 drug Drugs 0.000 title claims description 38
- 238000000034 method Methods 0.000 title claims description 11
- 210000003734 kidney Anatomy 0.000 title abstract description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 45
- 239000000843 powder Substances 0.000 claims description 45
- 239000000341 volatile oil Substances 0.000 claims description 45
- 239000008187 granular material Substances 0.000 claims description 42
- 239000009636 Huang Qi Substances 0.000 claims description 38
- 238000002360 preparation method Methods 0.000 claims description 33
- 241000208340 Araliaceae Species 0.000 claims description 28
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 28
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 28
- 235000008434 ginseng Nutrition 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 27
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 26
- 239000002994 raw material Substances 0.000 claims description 26
- 239000006071 cream Substances 0.000 claims description 24
- 208000037157 Azotemia Diseases 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 21
- 241000190633 Cordyceps Species 0.000 claims description 18
- 208000009852 uremia Diseases 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 15
- 201000006370 kidney failure Diseases 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 14
- 229920000858 Cyclodextrin Polymers 0.000 claims description 11
- 238000001291 vacuum drying Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000004821 distillation Methods 0.000 claims description 6
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- -1 oven dry (50~75 °C) Substances 0.000 claims description 3
- 239000007779 soft material Substances 0.000 claims description 3
- 241000756943 Codonopsis Species 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 21
- 230000006870 function Effects 0.000 abstract description 12
- 230000017531 blood circulation Effects 0.000 abstract description 11
- 230000001737 promoting effect Effects 0.000 abstract description 10
- 231100000331 toxic Toxicity 0.000 abstract description 10
- 230000002588 toxic effect Effects 0.000 abstract description 10
- 208000007536 Thrombosis Diseases 0.000 abstract description 8
- 210000000952 spleen Anatomy 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 5
- 238000010792 warming Methods 0.000 abstract description 3
- 208000031975 Yang Deficiency Diseases 0.000 abstract description 2
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 241001251949 Xanthium sibiricum Species 0.000 description 56
- 241000700159 Rattus Species 0.000 description 36
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 23
- 229930024421 Adenine Natural products 0.000 description 20
- 229960000643 adenine Drugs 0.000 description 20
- 230000001684 chronic effect Effects 0.000 description 19
- 208000020832 chronic kidney disease Diseases 0.000 description 12
- 230000037396 body weight Effects 0.000 description 10
- 230000008014 freezing Effects 0.000 description 9
- 238000007710 freezing Methods 0.000 description 9
- 230000004089 microcirculation Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 7
- 229930182837 (R)-adrenaline Natural products 0.000 description 7
- 101710113174 Corticoliberin Proteins 0.000 description 7
- 229960005139 epinephrine Drugs 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 230000000630 rising effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 230000003118 histopathologic effect Effects 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 5
- 101000895495 Rattus norvegicus Corticoliberin Proteins 0.000 description 5
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 5
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 5
- GBONBLHJMVUBSJ-FAUHKOHMSA-N corticorelin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)O)C(C)C)C1=CNC=N1 GBONBLHJMVUBSJ-FAUHKOHMSA-N 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 210000000713 mesentery Anatomy 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 4
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000001473 noxious effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 206010048469 Kidney enlargement Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 239000009320 niaoduqing keli Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 210000005085 renal fascia Anatomy 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 剂量(g/kg) | 动物(只) | Bun(mmol/L) | Crea(μmol/L) | ||
造模后 | 给药一个月 | 造模后 | 给药一个月 | |||
模型对照尿毒清双参苓双参苓正常对照 | -2.32.71.35- | 88888 | 18.32±3.39△△18.40±1.4218.39±2.2618.54±2.423.01±0.39 | 19.28±2.86△△13.56±3.01**14.45±2.18**17.26±3.513.41±0.57 | 193.75±53.85△△189.13±53.02195.13±57.30190.63±58.3669.38±15.50 | 214.75±56.71117.7±24.06**114.3±19.19**162.25±64.6577.88±10.60 |
组别 | 剂量(g/kg) | 动物数(n) | 血红蛋白Hb(g/L) |
正常对照模型对照尿毒清双参苓大双参苓小 | --2.302.701.35 | 88888 | 127.00±12.8069.60±8.50△△76.3±9.00**88.00±7.50**+79.00±6.10* |
组别 | 剂量(g/kg) | 动物(只) | Bun(mmol/L) | Crea(μmol/L) | ||
造模后 | 给药一个月 | 造模后 | 给药一个月 | |||
模型对照尿毒清双参苓双参苓双参苓正常对照 | -2.32.71.350.68- | 888888 | 26.28±6.4626.95±6.1726.17±3.9327.28±3.4626.86±3.514.17±1.12 | 23.98±6.00△△15.07±2.30**14.57±2.66**15.14±1.99**20.56±4.864.64±0.94 | 644.13±69.20639.25±97.21645.0±93.58643.38±67.59636.75±83.9879.38±12.27 | 361.63±76.82△△246.25±75.0**234.88±83.44**249.13±63.38**302.25±57.6174.13±10.60 |
组别 | 剂量(g/kg) | 动物(只) | Bun(mmol/L) | Crea(μmol/L) | ||
给药2W | 4W | 给药2W | 4W | |||
正常对照模型对照尿毒清双参苓双参苓双参苓 | -等容量2.32.71.350.68 | 888888 | 4.33±1.5129.81±5.90△△21.72±6.74*19.40±2.46**21.51±3.43**26.21±3.14 | 4.56±1.1516.95±1.51△△11.72±1.70**10.17±1.97**12.68±1.45**14.76±1.35** | 74.88±13.61679.25±94.40590.25±53.40*542.25±50.74**592.38±68.76**616.23±53.27 | 72.38±10.02355.63±59.70△△224.00±47.23**208.25±51.62**226.38±42.83**303.38±64.84 |
组别 | 剂量(g/kg) | 动物(只) | 给药六周 | ||
体重(g) | 肾脏重(g) | 肾脏系数(g/100g) | |||
模型对照尿毒清双参苓双参苓双参苓正常对照 | 等容量2.32.71.350.68- | 101010101010 | 168.75±22.00△△206.87±29.00**210.60±26.92**190.60±21.62*176.25±18.85221.25±32.71 | 2.15±0.33△△1.87±0.13*1.77±0.19**1.96±0.102.12±0.301.42±0.19 | 1.29±0.20△△0.94±0.09**0.85±0.08**1.03±0.11*1.20±0.210.66±0.08 |
组别 | 剂量(g/kg) | 动物数(n) | 血液粘度(低切变速率3/s) |
正常对照模型对照尿毒清 | --2.3 | 888 | 15.39±0.6916.64±0.78△△15.25±0.65** |
双参苓双参苓双参苓 | 2.71.350.68 | 888 | 14.60±0.39**+15.42±0.50**15.68±0.63* |
组别 | 剂量(g/kg) | 动物数(n) | 微循环恢复时间s′( X±SD) |
模型对照尿毒清双参苓双参苓双参苓 | -4.625.52.751.4 | 1010101010 | 163.40±21.60124.40±20.70△△81.30±12.60△△**140.50±19.98*148.7±15.16 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100212995A CN1325094C (zh) | 2004-04-14 | 2004-04-14 | 一种治疗尿毒症及肾阳虚、肾衰竭的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100212995A CN1325094C (zh) | 2004-04-14 | 2004-04-14 | 一种治疗尿毒症及肾阳虚、肾衰竭的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1682780A true CN1682780A (zh) | 2005-10-19 |
CN1325094C CN1325094C (zh) | 2007-07-11 |
Family
ID=35262399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100212995A Expired - Lifetime CN1325094C (zh) | 2004-04-14 | 2004-04-14 | 一种治疗尿毒症及肾阳虚、肾衰竭的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1325094C (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552431A (zh) * | 2012-02-17 | 2012-07-11 | 上海市中医医院 | 一种治疗造影剂肾病的组合药物 |
CN102698174A (zh) * | 2012-07-05 | 2012-10-03 | 杨万明 | 一种治疗慢性肾衰的药物及其制备方法 |
CN102743594A (zh) * | 2012-07-10 | 2012-10-24 | 刘金彦 | 一种治疗慢性肾功能衰竭的中药组合物 |
CN102824593A (zh) * | 2012-09-20 | 2012-12-19 | 杨卫彬 | 治疗慢性肾功能衰竭的中成药 |
CN103720836A (zh) * | 2013-12-20 | 2014-04-16 | 柳州市中医院 | 治疗慢性肾衰竭的中药及其制备方法 |
CN105125814A (zh) * | 2015-10-19 | 2015-12-09 | 管遵信 | 一种治疗慢性肾衰竭ⅲ,ⅳ期的中药组合物 |
CN105250588A (zh) * | 2015-10-19 | 2016-01-20 | 陈立爱 | 治疗肾功能衰竭的中药制剂及其制备方法 |
CN107485669A (zh) * | 2017-08-18 | 2017-12-19 | 广州市圆强医药科技有限公司 | 利用健生宝治疗肾病尿毒症的生物透析疗法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1387872A (zh) * | 2001-05-25 | 2003-01-01 | 张丰强 | 治疗肾病的药物及其加工方法 |
CN1466963A (zh) * | 2002-07-11 | 2004-01-14 | 山东百草药业有限公司 | 一种治疗肾病的肾舒胶囊及其制备方法 |
-
2004
- 2004-04-14 CN CNB2004100212995A patent/CN1325094C/zh not_active Expired - Lifetime
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552431A (zh) * | 2012-02-17 | 2012-07-11 | 上海市中医医院 | 一种治疗造影剂肾病的组合药物 |
CN102698174A (zh) * | 2012-07-05 | 2012-10-03 | 杨万明 | 一种治疗慢性肾衰的药物及其制备方法 |
CN102743594A (zh) * | 2012-07-10 | 2012-10-24 | 刘金彦 | 一种治疗慢性肾功能衰竭的中药组合物 |
CN102743594B (zh) * | 2012-07-10 | 2014-01-01 | 刘金彦 | 一种治疗慢性肾功能衰竭的中药组合物 |
CN102824593A (zh) * | 2012-09-20 | 2012-12-19 | 杨卫彬 | 治疗慢性肾功能衰竭的中成药 |
CN102824593B (zh) * | 2012-09-20 | 2014-05-07 | 杨卫彬 | 治疗慢性肾功能衰竭的中成药 |
CN103720836A (zh) * | 2013-12-20 | 2014-04-16 | 柳州市中医院 | 治疗慢性肾衰竭的中药及其制备方法 |
CN105125814A (zh) * | 2015-10-19 | 2015-12-09 | 管遵信 | 一种治疗慢性肾衰竭ⅲ,ⅳ期的中药组合物 |
CN105250588A (zh) * | 2015-10-19 | 2016-01-20 | 陈立爱 | 治疗肾功能衰竭的中药制剂及其制备方法 |
CN105125814B (zh) * | 2015-10-19 | 2019-11-08 | 管遵信 | 一种治疗慢性肾衰竭ⅲ,ⅳ期的中药组合物 |
CN107485669A (zh) * | 2017-08-18 | 2017-12-19 | 广州市圆强医药科技有限公司 | 利用健生宝治疗肾病尿毒症的生物透析疗法 |
Also Published As
Publication number | Publication date |
---|---|
CN1325094C (zh) | 2007-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1298363C (zh) | 一种辅助降血糖的保健食品及其制备方法 | |
CN1539459A (zh) | 一种治疗贫血的再造生血中药制剂及制备方法 | |
CN1233387C (zh) | 一种治疗失眠症的中药复方制剂及其制备方法 | |
CN1306848A (zh) | 防治白细胞减少症的中药制剂及制备工艺 | |
CN1682780A (zh) | 一种治疗尿毒症及肾阳虚、肾衰竭的药物及其制备方法 | |
CN1927331A (zh) | 一种治疗慢性心力衰竭的中药制剂 | |
CN1733025A (zh) | 一种治疗风湿、类风湿性疾病的药物组合物及制备工艺 | |
CN1478508A (zh) | 一种治疗脂肪肝的中药组合物及其制备方法 | |
CN1238024C (zh) | 治疗肾阳虚的中药及其制备方法 | |
CN1831015A (zh) | 贞芪多糖的提取工艺及其产品和它的应用 | |
CN100350940C (zh) | 治疗糖尿病及并发症的药物及其制备方法 | |
CN104998085B (zh) | 一种可增强免疫功能的中药复方组合物及其制备方法 | |
CN1424057A (zh) | 一种中药免疫调节剂及其制法和在制药中的应用 | |
CN100342888C (zh) | 一种治疗前列腺增生的中药制剂及其制备方法和应用 | |
CN1733089A (zh) | 治疗糖尿病及并发症的药物及其制备方法 | |
CN1679658A (zh) | 一种治疗艾兹病的中药制剂及其加工方法 | |
CN1234407C (zh) | 一种治疗慢性前列腺炎的药物及其制备方法 | |
CN1190228C (zh) | 安宫止血药物 | |
CN1042395C (zh) | 蚁王精口服液及其制备方法 | |
CN1682970A (zh) | 一种苦碟子注射制剂的制备方法 | |
CN1730023A (zh) | 一种抗肝炎病毒的中药制剂及其制备方法 | |
CN1679693A (zh) | 一种治疗肝病的药物及其制备方法 | |
CN1541691A (zh) | 治疗急性黄疸肝炎的中药及其制备方法 | |
CN1442165A (zh) | 一种治疗慢性肾炎的中药及其制备方法 | |
CN1314415C (zh) | 治疗皮肤疾病的中药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING YINKERUISI PHARMACEUTICAL TECHNOLOGY CO., Free format text: FORMER OWNER: ZHANG MINGMING ADDRESS Effective date: 20081121 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20081121 Address after: Beijing City, Xicheng District Xinfeng Street 2 Tiancheng Technology building block B room 3003 Patentee after: BEIJING INCREASE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Address before: D-20-10, 100 Binhe Road, Shenhe District, Shenyang, Liaoning, China Patentee before: Zhang Mingming |
|
ASS | Succession or assignment of patent right |
Owner name: BEIJING YINKERUISI PHARMACEUTICAL TECHNOLOGY CO., Free format text: FORMER OWNER: ZHANG MINGMING Effective date: 20081121 |
|
CP01 | Change in the name or title of a patent holder |
Address after: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee after: BEIJING INCREASE PHARMACEUTICAL INSTITUTE Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: BEIJING INCREASE PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Address after: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee after: BEIJING INCREASE PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: BEIJING INCREASE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP03 | Change of name, title or address |
Address after: Double camp 102299 West Road Beijing city Changping District Science Park No. 79, No. 24 building 6 layer cloud Valley Park Patentee after: Beijing Increasepharm Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: BEIJING INCREASE PHARMACEUTICAL INSTITUTE Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210310 Address after: No.6 Fengjing Avenue, Fengjing Industrial Park, Xi'an, Shaanxi 710300 Patentee after: XI'AN SHIJISHENGKANG PHARMACEUTICAL INDUSTRY Co.,Ltd. Address before: 102299 Beijing 6 Changping District science and Technology Park No. 79, No. 24, No. Patentee before: Beijing Increasepharm Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
DD01 | Delivery of document by public notice |
Addressee: Hao Peiqi Document name: Notification of eligibility |
|
DD01 | Delivery of document by public notice | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20070711 |
|
DD01 | Delivery of document by public notice |
Addressee: Hao Peiqi Document name: Notice of Termination of Patent Rights |